Last reviewed · How we verify
PALIPERIDONE — Competitive Intelligence Brief
marketed
Atypical Antipsychotic [EPC]
Small molecule
Live · refreshed every 30 min
Target snapshot
PALIPERIDONE (PALIPERIDONE).
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PALIPERIDONE TARGET | PALIPERIDONE | marketed | Atypical Antipsychotic [EPC] | 2006-01-01 | ||
| SAMIDORPHAN L-MALATE | SAMIDORPHAN L-MALATE | marketed | Atypical Antipsychotic [EPC] | dopamine and serotonin type 2 (5HT2) receptors, opioid receptors | 2021-01-01 | |
| Lybalvi | SAMIDORPHAN | Alkermes Inc | marketed | Atypical Antipsychotic [EPC] | Mu-type opioid receptor | 2021-01-01 |
| Caplyta | LUMATEPERONE | Intra-Cellular | marketed | Atypical Antipsychotic [EPC] | 5-hydroxytryptamine receptor 2A | 2019-01-01 |
| Nuplazid | PIMAVANSERIN | Acadia Pharms Inc | marketed | Atypical Antipsychotic | 5-hydroxytryptamine receptor 2A | 2016-01-01 |
| Rexulti | BREXPIPRAZOLE | Otsuka | marketed | Atypical Antipsychotic [EPC] | D(2) dopamine receptor | 2015-01-01 |
| Vraylar | CARIPRAZINE | AbbVie | marketed | Atypical Antipsychotic [EPC] | D(3) dopamine receptor | 2015-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Lybalvi · 11351166 · US
- — Lybalvi · 11241425 · US
- — Lybalvi · 9126977 · US
- — Lybalvi · 10300054 · US
- — Lybalvi · 10716785 · US
- — Lybalvi · 11185541 · US
- — Lybalvi · 9517235 · US
- — Lybalvi · 9119848 · US
- — Lybalvi · 8778960 · US
Sponsor landscape (Atypical Antipsychotic [EPC] class)
- · 2 drugs in this class
- AbbVie · 1 drug in this class
- Alkermes Inc · 1 drug in this class
- Eli Lilly · 1 drug in this class
- Hisamitsu · 1 drug in this class
- Intra-Cellular · 1 drug in this class
- Jazz Pharmaceuticals · 1 drug in this class
- Johnson & Johnson (Janssen) · 1 drug in this class
- Otsuka · 1 drug in this class
- Vanda Pharms Inc · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PALIPERIDONE CI watch — RSS
- PALIPERIDONE CI watch — Atom
- PALIPERIDONE CI watch — JSON
- PALIPERIDONE alone — RSS
- Whole Atypical Antipsychotic [EPC] class — RSS
Cite this brief
Drug Landscape (2026). PALIPERIDONE — Competitive Intelligence Brief. https://druglandscape.com/ci/paliperidone. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab